tapinarof
Selected indexed studies
- Tapinarof. (, 2006) [PMID:36701502]
- Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans. (J Invest Dermatol, 2017) [PMID:28595996]
- Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials. (J Am Acad Dermatol, 2024) [PMID:38777187]
_Worker-drafted node — pending editorial review._
Connections
tapinarof is a side effect of
Sources
- Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. (2021) pubmed
- Tapinarof. (2006) pubmed
- Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans. (2017) pubmed
- Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials. (2024) pubmed
- Tapinarof Cream 1%: First Approval. (2022) pubmed
- Tapinarof for the treatment of psoriasis. (2022) pubmed
- Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent. (2021) pubmed
- Tapinarof validates the aryl hydrocarbon receptor as a therapeutic target: A clinical review. (2024) pubmed
- Tapinarof cream for the treatment of plaque psoriasis: Efficacy and safety results from 2 Japanese phase 3 trials. (2024) pubmed
- Tapinarof cream for the treatment of atopic dermatitis: Efficacy and safety results from two Japanese phase 3 trials. (2024) pubmed